Jy Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 1.58 Cr
as on 17-11-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.88 Cr
as on 17-11-2024
- Satisfied Charges ₹ 2.40 Cr
as on 17-11-2024
- Revenue 25.54%
(FY 2023)
- Profit -47.23%
(FY 2023)
- Ebitda -13.77%
(FY 2023)
- Net Worth 0.54%
(FY 2023)
- Total Assets 15.89%
(FY 2023)
About Jy Pharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.58 Cr.
The company currently has active open charges totaling ₹7.88 Cr. The company has closed loans amounting to ₹2.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ravinder Dhanturi and Sudheer Guntupalli serve as directors at the Company.
- CIN/LLPIN
U24233TG2016PTC103819
- Company No.
103819
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jy Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravinder Dhanturi  | Director | 05-Mar-2022 | Current |
| Sudheer Guntupalli | Director | 05-Mar-2022 | Current |
Financial Performance of Jy Pharma.
Jy Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25.54% increase. The company also saw a substantial fall in profitability, with a 47.23% decrease in profit. The company's net worth moved up by a moderate rise of 0.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jy Pharma?
In 2023, Jy Pharma had a promoter holding of 38.00% and a public holding of 62.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Raveez Pharma Private LimitedActive 3 years 2 monthsRavinder Dhanturi and Sudheer Guntupalli are mutual person
- Dhanturi Group Of Hotels Private LimitedActive 17 years 1 month
Ravinder Dhanturi is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 04 Nov 2022 | ₹7.74 Cr | Open |
Hdfc Bank Limited Creation Date: 09 Aug 2021 | ₹1.45 M | Open |
Others Creation Date: 05 Aug 2019 | ₹2.40 Cr | Satisfied |
How Many Employees Work at Jy Pharma?
Jy Pharma has a workforce of 15 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jy Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jy Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
